stockrow
Saturday 7 November 2026
Export OLMA’s income statement to Excel — free account
Olema Pharmaceuticals, Inc.
OLMA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −54.3%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
7.30
0.54
+7.99%
Follow OLMA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 6 | 6 | 91 | +278.9% | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (2) | (4) | (22) | (71) | (105) | (97) | (129) | (162) | (205) | +84.9% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (2) | (4) | (22) | (71) | (105) | (97) | (129) | (162) | (205) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (0.87) | (1.66) | (3.42) | (1.80) | (2.62) | (2.14) | (2.20) | (1.87) | (2.12) | +11.5% | ||||||
| Cash flow | — | — | (0.86) | (1.19) | (2.83) | (1.28) | (2.05) | (1.85) | (1.78) | (1.69) | (1.58) | +10.1% | ||||||
| Capex | — | — | 0.00 | 0.00 | (0.01) | (0.04) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (0.86) | (1.19) | (2.84) | (1.32) | (2.06) | (1.85) | (1.78) | (1.69) | (1.58) | +10.1% | ||||||
| Book value | — | — | 1.22 | (0.48) | 48.16 | 7.20 | 4.94 | 5.61 | 6.96 | 5.50 | 4.12 | +24.0% | ||||||
| Shares, m | — | — | 3 | 3 | 7 | 40 | 40 | 45 | 59 | 87 | 95 | +65.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (2) | (3) | (20) | (51) | (82) | (84) | (104) | (147) | (165) | +82.5% | |||||
| Capex | — | — | — | — | 0 | (2) | 0 | 0 | 0 | — | 0 | +29.8% | ||||||
| Free cash flow | — | — | (2) | (3) | (20) | (52) | (82) | (84) | (105) | (147) | (165) | +82.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 3 | (1) | 338 | 282 | 192 | 245 | 397 | 464 | 417 | +105.1% | |||||
| Net debt | — | — | (3) | 0 | (339) | (285) | (203) | (262) | (434) | (502) | (458) | +106.4% | ||||||
| Shareholders’ equity | — | — | 3 | (1) | 338 | 285 | 198 | 254 | 409 | 479 | 431 | +105.7% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (134.33) | (253.66) | (13.99) | (22.26) | (40.97) | (39.24) | (35.57) | (33.00) | (47.10) | +101.3 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 26.04 | 51.16 | (14.65) | (22.83) | (43.47) | (42.82) | (39.07) | (36.61) | (52.74) | (62.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 22 | 37 | 74 | 86 | 74 | 96 | 131 | — | +34.6% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Olema Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GERN Geron Corporation | $610.4M | — (loss-making) | — (loss-making) | +27.45% (above 0%: growing) | n/m | +176.13% (above 0%: growing) | 89.95% | 9.63% | Compare |
| DSGN Design Therapeutics, Inc. | $605.2M | — (loss-making) | — (loss-making) | — | n/m | −7.00% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KURA Kura Oncology, Inc. | $604.9M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | Compare |
| AVBP ArriVent BioPharma, Inc. | $603.0M | — (loss-making) | — | — | n/m | −51.51% (below 0%: shrinking) | — | 0.00% | Compare |
| IMMX Immix Biopharma, Inc. | $596.9M | — (loss-making) | — | — | n/m | −116.22% (below 0%: shrinking) | — | 0.00% | Compare |
| OBX Obsidian Therapeutics, Inc | $593.0M | — | — | — | n/m | — | — | 0.00% | Compare |
| OLMA Olema Pharmaceuticals, Inc. | $591.5M | — (loss-making) | — | — | n/m | −54.33% (below 0%: shrinking) | 0.00% | 0.00% | |
| APMD Apnimed, Inc. | $589.5M | 0.8× | 4.6× | — | — | — | 89.98% | (96.89%) | Compare |
| NVCT Nuvectis Pharma, Inc. | $579.8M | — (loss-making) | — | — | n/m | −34.57% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $600.0M | — | — | — | — | −43.04% | 89.97% | 0.00% |
Pay and ownership Proxy statement filed 29 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 3.18m | 25.16m | 1,020.00 |
| 2024 | 8.13m | (4.60m) | 238.00 |
| 2023 | 3.15m | 22.26m | 573.00 |
Ownership
Directors and executive officers, together
12.56%
Entities affiliated with FMR LLC
11.45%
Entities affiliated with BVF Partners L.P.
9.99%
Bain Capital Life Sciences Opportunities IV, L.P.
9.99%
Entities affiliated with Paradigm BioCapital Advisors LP
9.99%
Entities affiliated with Janus Henderson Group PLC
7.68%
Entities affiliated with Invus Public Equities, L.P.
5.11%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement